Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-grade glioma

Needham, mass., nov. 11, 2022 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced presentation of late-breaking data from a phase 1 mechanistic clinical trial of can-2409, candel's lead viral immunotherapy in development, in combination with nivolumab and standard of care treatment in patients with high-grade glioma. data were presented at the 37th annual meeting of society for immunotherapy of cancer (sitc) today in boston.
CADL Ratings Summary
CADL Quant Ranking